SCHEMBL2247187

SCHEMBL2247187

CCCCCCNC(=O)[C@H](CCC(=O)O)NC(=O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.87

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.60
ADAMTS5 Q9UNA0 2/20 0.59
ADAMTS4 O75173 1/20 0.59
MEN1 O00255 1/20 0.54
ALDH1A1 P00352 1/20 0.54
HPGD P15428 1/20 0.54
KMT2A Q03164 1/20 0.54
FOLH1 Q04609 2/20 0.54
MMP2 P08253 1/20 0.53
MMP8 P22894 1/20 0.53
MMP12 P39900 1/20 0.53
NAAA Q02083 1/20 0.53
DRD2 P14416 1/20 0.53
DRD4 P21917 1/20 0.53
DRD3 P35462 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2244966 1.00 L3MBTL1 (0.60) L3MBTL1ADAMTS5ADAMTS4MEN1ALDH1A1
SCHEMBL2244204 0.99 L3MBTL1 (0.61) L3MBTL1ADAMTS5ADAMTS4FOLH1MMP2
SCHEMBL2250363 0.95 L3MBTL1 (0.62) L3MBTL1ADAMTS5ADAMTS4FOLH1MMP2
SCHEMBL2245265 0.91 L3MBTL1 (0.72) L3MBTL1ADAMTS5ADAMTS4MMP2MMP8
SCHEMBL2245808 0.90 ADAMTS5 (0.57) L3MBTL1ADAMTS5ADAMTS4FOLH1MMP2
SCHEMBL2250028 0.90 ADAMTS5 (0.57) L3MBTL1ADAMTS5ADAMTS4FOLH1MMP2
SCHEMBL3576470 0.89 MEN1 (0.53) MEN1ALDH1A1HPGDKMT2AFOLH1
SCHEMBL2249268 0.88 ADAMTS5 (0.58) L3MBTL1ADAMTS5ADAMTS4FOLH1MMP2
SCHEMBL2245397 0.86 FOLH1 (0.59) L3MBTL1ADAMTS5ADAMTS4FOLH1MMP2
SCHEMBL2246518 0.85 L3MBTL1 (0.58) L3MBTL1ADAMTS5ADAMTS4FOLH1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1902014-A2 GLUTAMATE AGGRECANASE INHIBITORS Wyeth (US) 2008-03-26 EP claimed
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US claimed
WO-2007008994-A2 GLUTAMATE AGGRECANASE INHIBITORS WYETH (US) 2007-01-18 WO claimed
US-7998965-B2 Glutamate aggrecanase inhibitors WYETH LLC (US) 2011-08-16 US disclosed
US-20100010012-A1 GLUTAMATE AGGRECANASE INHIBITORS WYETH (US) 2010-01-14 US disclosed
US-7553873-B2 Glutamate aggrecanase inhibitors WYETH (US) 2009-06-30 US disclosed
EP-1902014-A2 GLUTAMATE AGGRECANASE INHIBITORS Wyeth (US) 2008-03-26 EP disclosed
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US disclosed
WO-2007008994-A2 GLUTAMATE AGGRECANASE INHIBITORS WYETH (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010012-A1 GLUTAMATE AGGRECANASE INHIBITORS ADAMTS5, ADAMTS1, ADAMTS7 L3MBTL1 4308/4885ADAMTS5 1/4885ADAMTS4 5/4885
US-20070043066-A1 Glutamate aggrecanase inhibitors ADAMTS5, ADAMTS1, ADAMTS7 L3MBTL1 4308/4885ADAMTS5 1/4885ADAMTS4 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.